^
Association details:
Evidence:
Evidence Level:
Sensitive: D ā€“ Preclinical
New
Source:
Title:

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

Excerpt:
Interestingly, PDXs with MAP3K1 alterations were more sensitive to alpelisib (one-tailed pā€‰=ā€‰0.001), but not buparlisib.
DOI:
10.1038/s41523-019-0126-6